Background: Primary hyperparathyroidism (pHPT) is one of the most common endocrine diseases and the most common cause of hypercalcemia. Since routine laboratory testing, the prevalence of the disease has increased fro...Background: Primary hyperparathyroidism (pHPT) is one of the most common endocrine diseases and the most common cause of hypercalcemia. Since routine laboratory testing, the prevalence of the disease has increased from 0.1% to 0.4% worldwide. The only curative treatment is parathyroidectomy. Nowadays, preoperative localization studies have become standard before surgical treatment, and the first stage imaging methods are cervical ultrasonography (US) and/or Sestamibi scintigraphy. Objectives: To describe the accuracy of US and Sestamibi for detection of hyperfunctioning parathyroid adenomas preoperatively in patients with confirmed pHPT from our medical institution. Results: This is a retrospective study from a prospectively kept database that included thirty-one patients with the confirmed diagnosis of pHPT clinically and biochemically. The average age was 57.8 years old. Preoperative US and surgery findings were compared with a sensitivity of 51%. Preoperative Sestamibi and surgery findings were compared resulting in a sensitivity of 71%. Both imaging methods combined, resulted in a sensitivity of 80%. Conclusion: In patients with pHPT, Sestamibi is an effective method for localizing parathyroid pathology preoperatively, but the false negative rate can be high. US tends to have a wider range explained by the operator-dependent factor. The combination of US and Sestamibi reduces the rate of false negatives, as reported in international literature. It is important to mention that these studies cannot be used as a confirmatory test for this disease. It should only be used as an adjunct to help plan the operation.展开更多
组织病理学检查能确定甲状旁腺亢进症的病理类型,是鉴别甲状旁腺增生、甲状旁腺腺瘤和甲状旁腺癌的经典方法。近年来,甲状旁腺肿瘤及增生的免疫组织化学标记、分子病理学研究进展迅速,研究包括Cyc lin D1,MEN1,HRPT2和CaSR基因与蛋白。...组织病理学检查能确定甲状旁腺亢进症的病理类型,是鉴别甲状旁腺增生、甲状旁腺腺瘤和甲状旁腺癌的经典方法。近年来,甲状旁腺肿瘤及增生的免疫组织化学标记、分子病理学研究进展迅速,研究包括Cyc lin D1,MEN1,HRPT2和CaSR基因与蛋白。临床影像学技术的发展使甲状旁腺疾病的术前诊断更为准确,术中测定的甲状旁腺激素水平可作为评估手术疗效的指标。展开更多
文摘Background: Primary hyperparathyroidism (pHPT) is one of the most common endocrine diseases and the most common cause of hypercalcemia. Since routine laboratory testing, the prevalence of the disease has increased from 0.1% to 0.4% worldwide. The only curative treatment is parathyroidectomy. Nowadays, preoperative localization studies have become standard before surgical treatment, and the first stage imaging methods are cervical ultrasonography (US) and/or Sestamibi scintigraphy. Objectives: To describe the accuracy of US and Sestamibi for detection of hyperfunctioning parathyroid adenomas preoperatively in patients with confirmed pHPT from our medical institution. Results: This is a retrospective study from a prospectively kept database that included thirty-one patients with the confirmed diagnosis of pHPT clinically and biochemically. The average age was 57.8 years old. Preoperative US and surgery findings were compared with a sensitivity of 51%. Preoperative Sestamibi and surgery findings were compared resulting in a sensitivity of 71%. Both imaging methods combined, resulted in a sensitivity of 80%. Conclusion: In patients with pHPT, Sestamibi is an effective method for localizing parathyroid pathology preoperatively, but the false negative rate can be high. US tends to have a wider range explained by the operator-dependent factor. The combination of US and Sestamibi reduces the rate of false negatives, as reported in international literature. It is important to mention that these studies cannot be used as a confirmatory test for this disease. It should only be used as an adjunct to help plan the operation.
文摘组织病理学检查能确定甲状旁腺亢进症的病理类型,是鉴别甲状旁腺增生、甲状旁腺腺瘤和甲状旁腺癌的经典方法。近年来,甲状旁腺肿瘤及增生的免疫组织化学标记、分子病理学研究进展迅速,研究包括Cyc lin D1,MEN1,HRPT2和CaSR基因与蛋白。临床影像学技术的发展使甲状旁腺疾病的术前诊断更为准确,术中测定的甲状旁腺激素水平可作为评估手术疗效的指标。
